Liquid biopsies find distinct genomic profiles in most patients with carcinoma of unknown primary

(American Association for Cancer Research) Next-generation sequencing of circulating tumor DNA identified distinct genomic profiles with potentially targetable alterations in 99.7 percent of patients with carcinoma of unknown primary who have detectable alterations.